Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

APSTZD 1 — DRUG
APSTZD + placebo test 2 + placebo test 3 + placebo test 4 + comparator placebo 1
APSTZD 2 — DRUG
APSTZD + placebo test 1 + placebo test 3 + placebo test 4 + comparator placebo 1
APSTZD 3 — DRUG
APSTZD + placebo test 1 + placebo test 2 + placebo test 4 + comparator placebo 1
APSTZD 4 — DRUG
APSTZD + placebo test 1 + placebo test 2 + placebo test 3 + comparator placebo 1
Stilnox CR® — DRUG
Stilnox CR® + placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4
Placebo — DRUG
placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4 + comparator 1

The purpose of this study is to evaluate the efficacy of APSTZD compared to one active drug and placebo in insomnia treatment.

Experimental: APSTZD 1
5 oral tablets, once a day, before bedtime, for 6 weeks.
Experimental: APSTZD 2
5 oral tablets, once a day, before bedtime, for 6 weeks.
Experimental: APSTZD 3
5 oral tablets, once a day, before bedtime, for 6 weeks.
Experimental: APSTZD 4
5 oral tablets, once a day, before bedtime, for 6 weeks.
Active Comparator: Stilnox CR®
5 oral tablets, once a day, before bedtime, for 6 weeks.
Placebo Comparator: Placebo
5 oral tablets, once a day, before bedtime, for 6 weeks.

Reduction in WASO 6h (Wake After Sleep Onset) assessed by polysomnography [ Time Frame: Change from baseline after 2 weeks of treatment ]

Nationwide